Method for the identification of a risk for a thrombogenic...

Details Method for the identification of a risk for a thrombogenic... Method for the identification of a risk for a thrombogenic...

2011-07-26

2011-07-26

Yu, Melanie J (Department: 1641)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

C435S007900, C435S115000, C435S116000, C436S086000, C436S501000

Reexamination Certificate

active

07985562

ABSTRACT:
The present invention is directed to a method identifying a risk for a thrombogenic disorder, to a method for selecting patients with a risk for a thrombogenic disorder, to a method for identifying a pharmaceutical for the therapy or prophylaxis of a thrombogenic disorder as well as to a method for producing a medicament and a diagnostic by employing the TAFI-Ile347 polymorphism.

REFERENCES:
patent: 5593674 (1997-01-01), Drayna et al.
patent: 5747305 (1998-05-01), Jackson
patent: 5985562 (1999-11-01), Morser et al.
patent: 2005/0032703 (2005-02-01), Greenfield et al.
Boffa et al., Characterization of the Gene Encoding Human TAFI (Thrombin-Activable Fibrinolysis Inhibitor; Plasma Procarboxypeptidase B), Biochemistry, 1999, vol. 38, pp. 6547-6558.
Boffa et al., Thrombin Activable Fibrinolysis Inhibitor (TAFI): Molecular Genetics Of An Emerging Potential Risk Factor For Thrombotic Disorders, Current Drug Targets, Bentham Science Publ., 2001, vol. 1, No. 2, pp. 59-74.
Brouvers et al., A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFl leveis, Blood, Sep. 15, 2001, vol. 98, No. 6, pp. 1992-1993.
Franco et al., Identification of polymorphisms in the 5′-untranslated region of the TAFI gene: relationship with plasmaTAFI levels and risk of venous thrombosis, Haematologica, 2001, vol. 86, pp. 510-517.
Henry et al., Identification of polymorphisms in the promoterand the 3′ region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled, Blood, Apr. 1, 2001, vol. 27, No. 7, pp. 2053-2058.
Montaner et al., Thrombin-Activable Fibrinolysis Inhibitor Levels in The Acute Phase of Ischemic Stroke, Stroke, American Heart Assn., Apr. 2003, vol. 34, No. 4, pp. 1038-1040.
Santamaria et al., Risk of Ischemic Stroke Associated With Functional Thrombin-Activatable Fibrinolysis Inhibitor Plasma Levels, Stroke, American Heart Assn. , Oct. 2003, vol. 34, No. 10, pp. 2387-2391.
Schneider et al., Two naturally occurring variants of TAFI (Thr-325 and lle-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme, J. of Biol. Chem., Jan. 11, 2002, vol. 277, No. 2, pp. 1021-1030.
Van Theil et al., Low Levels of Thrombin Activatable Fibrinolysis Inhibitor (TAFI) in Patients With Chronic Liver Disease, Thrombosis and Haemostasis,Apr. 2001, vol. 85, No. 4, pp. 667-670.
Zorio et al., Thrombin-activable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolylic functin and the protein C system, Brit. Journal of Haematology, Sep. 2003, vol. 122, No. 6, pp. 956-965.

Affiliated with

Also associated with

Rating

Method for the identification of a risk for a thrombogenic... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for the identification of a risk for a thrombogenic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the identification of a risk for a thrombogenic... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2678178